Valeant and Pershing Plaza capital plan to jointly acquire aligen pharmaceutical

Source: Ding Xiangyuan April 21, 2014, Valeant pharmaceutical disclosed in a U.S securities trading application that it reached an agreement with Pan Xing square capital management company, a radical investor, on the joint acquisition of aligen pharmaceutical in February "Valeant's merger with aligen will create an unparalleled platform for medical growth and value creation, and we expect this to be finalized soon and the terms of the proposal to be announced soon," Valeant said Valeant said it plans to offer elgen shares and about $15 billion in cash In addition, Pershing Plaza has acquired about 10% of Ericsson's shares since the agreement was signed in February If the two companies finally merge, the capital management fund will retain the main part of the combined entity Pershing Plaza also agreed to hold at least $1.5 billion worth of Valeant's shares for at least one year after the closing of its acquisition of Ericsson, according to documents Valeant submitted to the securities and Exchange Commission After the news, erican and Valeant's shares rose about 19% and 11%, respectively Information indicates that the total value of the transaction will be slightly higher than $45 billion According to the Wall Street Journal, it is not clear to what extent the negotiations between Valeant and Ericsson have been conducted Elgen and Pershing square declined to comment Valeant CEO Mike Pearson said at the beginning of this year that as part of its plan to become the world's top five pharmaceutical companies by the end of 2016, the company is in the process of making acquisitions In August last year, the company bought boshlan for $8.7 billion Prior to that, Valeant acquired oubangqi in April 2013 for approximately $417 million, and also acquired Medicis pharmaceuticals for $2.6 billion Original link: http:// TSID = 28 & region? Id = 2? Axzz2zzxd8dtg